Anandamide VS CBD: ʻO wai ka mea ʻoi aku ka maikaʻi no kou olakino? ʻO nā mea āpau āu e ʻike ai e pili ana iā lākou!

Anandamide, ʻo ia hoʻi ʻo N-arachidonoylethanolamine, kahi neurotransmitter waikawa momona i lawe ʻia mai ka metabolism non-oxidative o eicosatetraenoic acid, kahi omega-6 fatty acid pono. Lawe ʻia ka inoa mai ka huaʻōlelo Sanskrit ananda, ʻo ia hoʻi "hauʻoli, hauʻoli, hauʻoli", a me amide.

Hāʻawi ka noiʻi i ka loulou mua ma waena o ka oxytocin - i kapa ʻia ʻo "hormone aloha" - a me anandamide, i kapa ʻia ʻo "mole mole hauʻoli" no kāna hana i ka hoʻoulu ʻana i nā pūkana cannabinoid i loko o nā lolo e hoʻonui i ka hoʻoikaika a me ka hauʻoli.

I ka hopena, ʻo nā mea loaʻa cannabinoid o ka ʻano CB1 a me ko lākou ligand endogeneous, anandamide, i loko o ka kaohi o ka neuronal excite .

Kuhi nā kānaka noiʻi aia paha he kolu o ka poʻe loaʻa cannabinoid e kali ana e ʻike ʻia. ʻO Endocannabinoids nā mea a ko mākou kino e hana maoli ai e hoʻonāukiuki i kēia mau mea loaʻa. Ua kapa ʻia nā mea ʻelua i maopopo loa o kēia mau molekiola anandamide a me 2-arachidonoylglycerol (2-AG).

ʻO ka ʻōnaehana cannabinoid endogenous - kapa ʻia no ka mea kanu i alakaʻi ʻia i kona loaʻa ʻana - kekahi o nā ʻōnaehana physiologic nui e pili ana i ka hoʻokumu a mālama ʻana i ke olakino kanaka. Loaʻa nā endocannabinoids a me kā lākou mau pane i loko o ke kino: i ka lolo, nā ʻokena, nā mea hoʻopili, nā glands, a me nā hunaola pale.

I ka 1992, ua hoʻokaʻawale ka hale hana o Mechoulam i ka endocannabinoid mua: kahi mole i hoʻokaʻawale ʻia ma ke ʻano he agonist hapa CB1. Ua ʻike ʻia ʻo ia ʻo arachidonoyl ethanolamide a kapa ʻia ʻo anandamide.

ʻAʻole loaʻa ʻo THC i ka kokoleka. Akā, ua hoʻokaʻawale ʻia kekahi kemika, kahi neurotransmitter i kapa ʻia ʻo anandamide. ʻO ka mea e mahalo ai, hana maoli ʻia ka anandamide i ka lolo.

Kāhea ʻia ʻo Anandamide he endocannabinoid no ka mea hana ʻia e ko mākou kino a hoʻohālikelike i nā cannabinoids i loaʻa i ka mea kanu mariuana. No laila, hiki i kahi mea hana i ka kokoleka a me kahi mea hana i ka mea kanu mariuana ke hoʻoulu i ka ʻōnaehana neurotransmitter marijuana ponoʻī o ko mākou lolo.

ʻO Theobromine ka alkaloid kumu i loaʻa i ka koko a me ke kokoleka. Hiki ke hoʻololi i ka pauka Cocoa i ka nui o kaobobine, mai ka 2% theobromine, a i ke kiʻekiʻe kiʻekiʻe ma kahi o 10%. … ʻOi aku ka nui o nā konsentrations i ka pouli ma mua o ka kokoleka waiū.

ʻO nā cannabinoid nui ʻelua ʻo delta-9-tetrahydrocannabinol (THC) a me cannabidiol (CBD). ʻO ka delta-9-tetrahydrocannabinol (THC) ka mea i ʻike pinepine ʻia o nā mea ʻelua, ʻo ia ka kemikona e kuleana i nā hopena psychoactive o ka cannabis.

ʻO Anandamide kahi kemikala lolo liʻiliʻi i ʻike ʻia i kapa ʻia ʻo ka “mole mole hauʻoli” no ka hana e hana ai i ka hauʻoli. … Hana ia ma ke hoʻopaʻa ʻana i nā mea loaʻa like i ka lolo me ka compound psychoactive nui i ka mariuana.

Anandamide, kahi lālani endogenous no ka lolo cannabinoid CB1 nā mea loaʻa, hana i nā hopena ʻano like ʻole e like me ka Δ9-tetrahydrocannabinol (THC), ke kumu psychoactive nui i ka mariuana.

Endocannabinoids. ʻO Endocannabinoids, i kapa ʻia he endogenous cannabinoids, he mau mole i hana ʻia e kou kino. Ua like lākou me nā cannabinoids, akā hana ʻia e kou kino.

Hoʻoikaika pū ʻo CBD i ka receptor adenosine e paipai i ka hoʻokuʻu ʻana o glutamate a me nā neurotransmitters dopamine. Ma o ka launa pū ʻana me nā receptor dopamine, kōkua ia e hāpai i nā pae dopamine a hoʻoponopono i ka ʻike, ka hoʻoikaika, a me nā ʻano ʻimi ʻimi uku.

hoʻemi i ka ʻehaʻeha. hoʻonui i ka ʻai. hoʻonui i ka dopamine (kahi neurotransmitter e kōkua i ka mālama ʻana i ka uku o ka lolo a me nā kikowaena leʻaleʻa) no ka hana manawa pō.

Ma waho aʻe o ke kō, loaʻa pū kekahi i ka kokoleka i ʻelua mau lāʻau neuroactive, caffeine a me theobromine. ʻAʻole wale ka kokoleka e hoʻonāukiuki i nā mea loaʻa i ka opiate i ko mākou lolo, ʻo ia ke kumu o ka hoʻokuʻu ʻia o nā neurochemicals i nā kikowaena leʻaleʻa o ka lolo.

Hoʻokumu ko mākou kino i ka anandamide ma ke koi, e hoʻohana ʻia inā pono e mālama i ka homeostasis. Hana ʻo Anandamide i kēia me ke kōkua ʻana i ka hoʻoponopono ʻana i ka mumū a me ka hōʻailona neuron. E like me ka mea i hana ʻia, paʻa paʻa mua ia me kā mākou mau pūkana cannabinoid CB1 a me CB2 e like me nā cannabinoids e like me THC i ka lawe ʻia ʻana.

ʻO nā mea loaʻa Cannabinoid, aia ma loko o ke kino, kahi ʻāpana o ka ʻōnaehana endocannabinoid, i pili i nā ʻano hanana physiological me ka makemake, ka ʻeha, ka naʻau, a me ka hoʻomanaʻo. ʻO nā mea loaʻa Cannabinoid he papa ia o nā receptor membrane cell i ka superfamily receptor protein G.

ʻO nā hui hana Anandamide e komo pū me nā amides, esters, a me nā ether o nā lālani momona polyunsaturated lōʻihi lōʻihi, a kaʻana like i nā pharmacophores koʻikoʻi me D-9-tetrahydrocannabinol (THC).

E ʻai i ka papaʻai momona i kēia mau huaʻai a kāohi i kāu hana FAAH e hoʻonui ai i kāu pae anandamide. ʻO ka kokoleka kekahi meaʻai e hiki ke kōkua i ka hoʻonui ʻana i ka anandamide. Loaʻa iā ia kahi pūhui i kapa ʻia ʻo ethylenediamine e kāpae ai i ka hana FAAH. E hoʻomanaʻo i kēia mau meaʻai ʻekolu i ka manawa aʻe āu e hele ai i ka supermarket.

ʻAʻole loaʻa ʻo THC i ka kokoleka. Akā, ua hoʻokaʻawale ʻia kekahi kemika, kahi neurotransmitter i kapa ʻia ʻo anandamide. ʻO ka mea e mahalo ai, hana maoli ʻia ka anandamide i ka lolo.

He kō ke kō he nui o ke kō. Ma waho aʻe o ke kō, loaʻa pū kekahi i nā kokoleka i ʻelua mau lāʻau neuroactive, caffeine a me theobromine. ʻAʻole wale ka kokoleka e hoʻonāukiuki i nā mea loaʻa i ka opiate i ko mākou lolo, ʻo ia ke kumu o ka hoʻokuʻu ʻia o nā neurochemicals i nā kikowaena leʻaleʻa o ka lolo.

ʻO Theobromine ka alkaloid kumu i loaʻa i ka koko a me ke kokoleka.

ʻO Theobromine, i ʻike ʻia ma mua he xantheose, kahi alkaloid ʻawaʻawa o ka cacao mea kanu, me ke ʻano kemika C7H8N4O2. Loaʻa iā ia i loko o ke kokoleka, a me kekahi mau meaʻai ʻē aʻe, e like me nā lau o ka mea kanu tī, a me ka kola nut.

Eia nō naʻe, no ka loaʻa ʻana o ka tryptophan i ka kokoleka, hiki i ka hoʻonui ʻia ʻana o ka serotonin ke kōkua i ka wehewehe ʻana no ke aha e hauʻoli ai kekahi, ʻoluʻolu, ai ʻole hopohopo ʻole ma hope o ka ʻai ʻana i kahi ʻāpana o kā lākou kokoleka (Serotonin).

He mea nui ʻo Anandamide i ke kaohi o ka hana hānai, a me ka hanauna neural o ka hoʻoikaika a me ka leʻaleʻa. Hoʻokomo pololei ʻia ʻo Anandamide i loko o ka forebrain e pili ana i ka lolo e pili ana i ka nucleus accumbens e hoʻonui i nā pane leʻaleʻa o nā ʻiole i kahi ʻono sucrose maikaʻi, a hoʻonui i ka ʻai pū kekahi.

ʻO THC a me CBD he mau antioxidant mana loa-ʻoi aku ka ikaika ma mua o ka wikamina C a me E. ʻO ka ʻoiaʻiʻo, ʻo ka US Government Patent 1999/008769 no ka neuroprotectant a me nā waiwai antioxidant o nā cannabinoids.

Fatty acid amide hydrolase (FAAH) kahi mammalian integral membrane enzyme e hoʻohaʻahaʻa i ka ʻohana momona amide ʻohana o nā endogenous lipaling lipids, kahi e komo pū ana me ka endogenous cannabinoid anandamide a me ka mea hoʻomoe e hoʻomoe ai.

Hōʻike nā noiʻi biochemical e hiki i ka cannabidiol ke hoʻonui i ka endandamous anandamide hōʻailona hōʻailona ʻole, ma ka pale ʻana i ka hoʻohaʻahaʻa intracellular o anandamide catalyzed e ka enzyme fatty acid amide hydrolase (FAAH).

ʻO ka huaʻōlelo cannabinoid e pili ana i kēlā me kēia mea kemikolo, me ka nānā ʻole i ke ʻano a me ke kumu, i hui pū ʻia me nā mea loaʻa lāʻau cannabinoid o ke kino a me ka lolo a he ʻano like nā hopena i hana ʻia e ka mea kanu ʻo Cannabis Sativa. … ʻO nā cannabinoid nui ʻelua ʻo delta-9-tetrahydrocannabinol (THC) a me cannabidiol (CBD).

Aia i loko o ke kino o ke kanaka kahi ʻōnaehana kūikawā i kapa ʻia ka endocannabinoid ʻōnaehana (ECS), pili i ka hoʻoponopono ʻana i nā ʻano hana like ʻole me ka hiamoe, ka makemake, ka ʻeha a me ka pane ʻana o ka ʻōnaehana pale.

ʻO nā mea loaʻa Cannabinoid, aia ma loko o ke kino, kahi ʻāpana o ka ʻōnaehana endocannabinoid, i pili i nā ʻano hanana physiological me ka makemake, ka ʻeha, ka naʻau, a me ka hoʻomanaʻo. … I ka makahiki 2007, ua wehewehe ʻia ka paʻa ʻana o kekahi mau cannabinoids i ka GPR55 i loaʻa pū me ka protein G i ka lolo.

E pili ana i ka hopena hilinaʻi o ka receptor cannabinoid o CBD ma ke aʻo ʻana i ka makaʻu makaʻu i hōʻike ʻia ma luna, hoʻonui ʻo CBD i nā pae anandamide ma o ka pāpā ʻana i kāna lawe ʻana i waena o ka lawe a me ka hoʻohaʻahaʻa ʻia e FAAH.

Me kahi mahele haʻahaʻa o THC a me kahi mahele o CBD, kūpono kūpono ʻo Harlequin's cannabinoid profile no nā mea hakakā hopohopo e noʻonoʻo ʻole i ka euphoria mālie. ʻO kāna terpene nui loa ka myrcene, ka mea i manaʻo ʻia he hopena hoʻomaha a hoʻohana ʻia i loko o ka mōʻaukala ma ke ʻano he mea kōkua moe.

Hoʻohana mau ʻia ʻo CBD e hoʻoponopono i ka hopohopo, a no nā mea maʻi e ʻeha ma o ka pilikia o ka hiamoe, hōʻike nā noiʻi e kōkua paha ʻo CBD me ka hiamoe ʻana a me ka hiamoe ʻana. Hāʻawi paha ʻo CBD i kahi koho no ka mālama ʻana i nā ʻano ʻeha mau o ka ʻeha mau.

ʻO ka waiʻona ka mea hoʻohiamoe a hoʻohaʻahaʻa e hoʻololi i ka ʻōnaehana waena. I ka manawa mua, hiki i ka inu ʻana ke hōʻemi i ka makaʻu a lawe i kou manaʻo mai kāu mau pilikia. Hiki iā ia ke kōkua iā ʻoe e hōʻemi i ka hilahila, hāʻawi iā ʻoe i ka hoʻoikaika i ka naʻau, a hoʻomaha iā ʻoe e hoʻomaha maʻamau.

No ke kuhi ʻana i kahi maʻi pīhoihoi, hana ke kauka i kahi hoʻokolohua kino, nīnau e pili ana i kāu mau hōʻailona, ​​a paipai i kahi hoʻokolohua koko, e kōkua ai i ke kauka e hoʻoholo inā loaʻa kekahi maʻi, e like me hypothyroidism. E nīnau paha ke kauka e pili ana i nā lāʻau āu e lawe nei.

• Nā Antidepressants (e like me fluoxetine, a i ʻole Prozac)
• Nā lāʻau i hiki ke hoʻoulu i ka hiamoe (antipsychotics, benzodiazepines)
• Nā lāʻauʻalopelo Macrolide (erythromycin, clarithromycin)
• Nā lāʻau puʻuwai (kekahi o nā blockers o ka puna calcium)

Hoʻoikaika pū ʻo CBD i ka receptor adenosine e paipai i ka hoʻokuʻu ʻana o glutamate a me nā neurotransmitters dopamine. Ma o ka launa pū ʻana me nā receptor dopamine, kōkua ia e hāpai i nā pae dopamine a hoʻoponopono i ka ʻike, ka hoʻoikaika, a me nā ʻano ʻimi ʻimi uku.

ʻO kekahi o nā hōʻailona a me nā ʻōuli o nā kūlana e pili ana i ka hemahema o ka dopamine e komo pū ana me: nā ʻūʻī, nā ʻū, a me nā haʻalulu. ʻeha a me nā ʻeha. ʻoʻoleʻa i nā mākala.

ʻO Caffeine, ka mea psychoactive i hoʻohana nui ʻia i ka honua, hoʻohana ʻia e hāpai i ka makaʻala a hoʻonui i ka makaʻala. E like me nā lāʻau hoʻōla hoʻolauna ʻē aʻe (stimulants a me modafinil), hoʻonui ka caffeine i ka dopamine (DA) e hōʻailona ana i ka lolo, ka mea e hana nui ʻia e nā antagonizing adenosine A2A receptors (A2AR).

• ʻAi i ka Protein he nui
• E ʻai i ka momona momona
• Pau Probiotics
• E ʻai i nā pīni Vvett
• Hoʻomaʻamaʻa pinepine
• Loaʻa i ka hiamoe nui
• Hoʻolohe i ke mele
• E noʻonoʻo
• E kiʻi i ka uila
• E noʻonoʻo i nā mea hoʻohui

Hoʻohana mau ʻia ʻo CBD e hoʻoponopono i ka hopohopo, a no nā mea maʻi e ʻeha ma o ka pilikia o ka hiamoe, hōʻike nā noiʻi e kōkua paha ʻo CBD me ka hiamoe ʻana a me ka hiamoe ʻana. Hāʻawi paha ʻo CBD i kahi koho no ka mālama ʻana i nā ʻano ʻeha mau o ka ʻeha mau.

ʻAʻole pono ʻo CBD e hoʻonui i nā pae serotonin, akā e hoʻopili paha ia i ka hopena o ka hopena o ka hopena o ka lolo i ka serotonin i loko o kāu ʻōnaehana. Ua ʻike ʻia kahi noiʻi holoholona 2014 i ka hopena o CBD ma luna o kēia mau mea loaʻa i ka lolo i hana i nā hopena antidepressant a me anti-hopohopo.

Manaʻo nā kānaka noiʻi he hiki i ka CBD ke hana ma ka ʻōnaehana endocannabinoid a me nā ʻōnaehana hōʻailona lolo ʻē aʻe ke hāʻawi i nā pono no ka poʻe me nā maʻi neurological. ʻO ka ʻoiaʻiʻo, ʻo kekahi o nā hoʻohana i aʻo ʻia no ka CBD i ka mālama ʻana i nā maʻi neurological e like me ka epilepsy a me nā sclerosis he nui.

• ai
• hoʻokō '
• Mālamalama kukui
• kumukanawai a
• lomilomi
• Hoʻokomo ʻia ka nohona

ʻO Anandamide kahi mea waena lipid e hana ma ke ʻano he ligand endogenous o nā mea loaʻa CB1. ʻO kēia mau receptor ka pahuhopu mole molaki mua ke kuleana no ka hopena lāʻau o Δ9-tetrahydrocannabinol, ka mea psychoactive ma Cannabis sativa.

Hoʻolālā ʻia ia mai ka N-arachidonoyl phosphatidylethanolamine e nā ala he nui. Hoʻohaʻahaʻa ʻia ia e ka fatty acid amide hydrolase (FAAH) enzyme, e hoʻohuli i ka anandamide i ethanolamine a me arachidonic acid.

Eia naʻe ka mea āu e ʻike ʻole ai, eia kēia ma muli o ka hana maoli ʻana o ke kino o ke kanaka i kāna iho endogenous cannabinoids: kūlike kūlike o nā pūhui i loaʻa i ka mea kanu cannabis, e like me THC (tetrahydrocannabinol) a me CBD (cannabidiol).

ʻAʻohe mea hōʻike, no ka laʻana, hoʻōla ʻo CBD i ka maʻi ʻaʻai. Aia kahi hōʻike kūpono e hiki ai i ka CBD ke hoʻomaikaʻi i nā maʻi hiamoe, ʻeha fibromyalgia, spasticity muscle e pili ana i nā sclerosis he nui, a me ka hopohopo. "ʻO ka pōmaikaʻi nui aʻu i ʻike ai ma ke ʻano he kauka i ka mālama ʻana i nā maʻi hiamoe, ka hopohopo, a me ka ʻeha," wahi a Kauka Levy.

Hāpai kekahi ʻo CBD i kekahi mau pilikia. ʻOiai ʻoluʻolu maikaʻi ʻia ia, hiki i ka CBD ke hana i nā hopena ʻaoʻao, e like me ka waha maloʻo, ka palahū, hoʻoliʻiliʻi ka makemake, ka hiamoe a me ka luhi. Hiki i ka CBD ke launa pū me nā lāʻau ʻē aʻe āu e lawe nei, e like me nā mea hōʻemi koko.

Pili kēia mau ʻano i ka hiki i ka CBD ke hana ma nā mea loaʻa o ka lolo no ka serotonin, kahi neurotransmitter e hoʻoponopono ana i ka naʻau a me ka nohona kanaka. Hōʻuluʻulu Manaʻo ʻana e hōʻike ana i ka CBD e hōʻemi i ka hopohopo a me ke kaumaha i loko o nā kānaka a me nā holoholona.

Noho mau ʻo CBD i kāu ʻōnaehana no 2 a 5 mau lā, akā ʻaʻole pili kēlā pae i nā mea āpau. No kekahi, hiki i ka CBD ke noho i loko o kā lākou ʻōnaehana no mau pule.

Hoʻokomo ʻia ʻo Anandamide i kahi enzymatically i nā wahi o ka lolo i mea nui i ka hoʻomanaʻo, nā hana noʻonoʻo a me ka kaohi o ka neʻe. Hōʻike ka noiʻi e hana nui ka anandamide i ka hana a me ka haki ʻana o nā pilina wā pōkole ma waena o nā pūnaewele nerve, a pili kēia i ke aʻo ʻana a me ka hoʻomanaʻo

Kapa pū ʻia ʻo N-arachidonoylethanolamine (AEA), hui pū ʻo anandamide me nā receptor CB o ke kino e like me nā cannabinoids e like me THC. He neurotransmitter a me ka mea hoʻopaʻa paʻa hiki i ka cannabinoid-receptor e hana nei ma ke ʻano he elele hōʻailona no nā mea loaʻa CB i loko o ke kino.